İçeriğe geç

The Evidence Base

@theevidencebase.bsky.social did:plc:pb4wpto3rgocga55xxqs6ecg

Providing the latest news, opinion and insight into hot topics including real-world data, health economics and outcomes research and patient-centric care.

Bluesky’a katılma tarihi:

Takipçi
119
Takip edilen
72
Post
608
Sıralamaya girdiği gün
0

Özet

The Evidence Base (@theevidencebase.bsky.social), 6 Aralık 2024 tarihinde katılan bir Bluesky kullanıcısı. 119 takipçisi var, 72 hesabı takip ediyor ve 608 post paylaştı.

Sıralama geçmişi

Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.

Bu hesap henüz günlük sıralamaya girmedi.

Son beğendiği postlar

Bluesky ağındaki herkese açık beğeniler.

  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New article alert Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort study 🔗 becarispublishing.com/doi/10.57264... #OpenAccess #JCER

    Postu göster
  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New article alert New Perspective article on "Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial" 🔗Read here: becarispublishing.com/doi/10.57264... #OpenAccess #JCER #TrialMethodology #RealWorldEvidence #RWE

    Postu göster
  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New article alert New Research Article on “Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer”. 🔗Read here: becarispublishing.com/doi/10.57264... #OpenAccess #JCER #ColorectalCancer #Oncology #ITC

    Postu göster
  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New Research Article alert "Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective" 🔗 becarispublishing.com/doi/10.57264... #OpenAccess #JCER #KidneyDisease

    Postu göster
  • Journal of Comparative Effectiveness Research@journal-cer.bsky.social

    📢New article alert New Short Report on "First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis". 🔗Read here: becarispublishing.com/doi/10.57264... #OpenAccess

    Postu göster

Daha fazlası için üye girişi yap

Blokladığı hesaplar

Bluesky’da bloklar herkese açık kayıtlardır.

Bu hesap kimseyi bloklamıyor.